Effects of PH3 in Diabetic Nephropathy.

Trial Profile

Effects of PH3 in Diabetic Nephropathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2015

At a glance

  • Drugs PHN 031 (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 25 Nov 2013 Planned end date changed from 1 Sep 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 25 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top